12/10
07:18 am
xers
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Xeris Biopharma (NASDAQ:XERS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
12/9
11:27 am
xers
Rating for XERS
Low
Report
Rating for XERS
12/9
11:27 am
xers
Rating for XERS
Low
Report
Rating for XERS
12/8
05:04 pm
xers
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
12/8
04:28 pm
xers
Xeris Biopharma initiated with an Overweight at Barclays
Low
Report
Xeris Biopharma initiated with an Overweight at Barclays
12/8
04:28 pm
xers
Xeris Biopharma initiated with an Overweight at Barclays
Low
Report
Xeris Biopharma initiated with an Overweight at Barclays
11/12
08:11 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/12
08:11 am
xers
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.
Low
Report
Xeris Biopharma (NASDAQ:XERS) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $18.00 price target on the stock.